È possibile coniugare risparmio e miglioramento nelle aziende USL?

• Main Author: Sergio Sabbatani
• Format: Article
• Language: English
• Published: SEEd Medical Publishers 2000-06-01
• Series: Farmeconomia: Health Economics and Therapeutic Pathways
• Online Access: https://journals.seedmedicalpublishers.com/index.php/FE/article/view/713

The present study aimed to evaluate if it’s possible to reduce the costs for the anti-infective medicine in a ward for the infectious disease. Analytic accounts data, related to the cost for three kind of drugs (antibiotic, antimicrobic and antriretroviral) will be presented. The analytic account is referred to the Bologna USL Firm (Presidi ospedalieri Bellaria and Maggiore) and to the Hospital Unit for the infectious disease (Ospedale Maggiore) in the year 1999. The Hospital Unit for the infectious disease consists of two ward for day of stay (32 beds), one day hospital for 10 beds and one divisional outpatients’ clinic. In 1999 there were 650 hospitalized (and discharged) patients and 783 day hospital patients. The overall cost for the Bologna USL Firm was L. 11.068.023.000, accounting L. 7.253.846.000 (65.5%) for the antiretroviral drug, L. 1.958.115.000 (17%) for the antibiotic drug and L. 1.856.062.000 (16.8%) for the antimicrobic drug and other antinfective medicine. The expenditure for the Hospital Unit for the infectious disease was L. 7.543.851.000, accounting L. 7.008.163.000 (92.9%) for the antiretroviral drug, L. 256.167.000 (3.4%) for the antibiotic drug and L. 279.521.000 (3.7%) for the antimicrobic drug and other antinfective medicine.